Edesa Biotech
EDSA
28 hedge funds and large institutions have $13.8M invested in Edesa Biotech in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 7 closing their positions.
219% more capital invested
Capital invested by funds: $4.34M → $13.8M (+$9.49M)
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
27% more funds holding
Funds holding: 22 → 28 (+6)
4.96% less ownership
Funds ownership: 36.63% → 31.67% (-5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.69M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$420K |
| 3 |
Jane Street
New York
|
+$347K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$105K |
| 5 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
+$91.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.97M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$888K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$191K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$77.8K |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$76.7K |
EDSA Hedge Fund Activity: Q1 2026 in Review
28 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q1 2026, worth a combined $13.8M — up 219% from $4.34M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new EDSA positions and 7 closed out — a net gain of 8 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.69M. The largest seller was Stonepine Capital Management, cutting an estimated $1.97M.
- 28 institutional investors held Edesa Biotech (EDSA) as of Q1 2026, up from 22 in Q4 2025.
- Funds reported $13.8M of Edesa Biotech stock for Q1 2026, up 219% quarter-over-quarter.
- 15 funds opened new Edesa Biotech positions in Q1 2026 and 7 closed out, a net change of +8 holders.
- The largest Edesa Biotech buyer in Q1 2026 was Perceptive Advisors, an estimated $1.69M added.
- The largest Edesa Biotech seller in Q1 2026 was Stonepine Capital Management, an estimated $1.97M sold.
Based on aggregated 13F filings for Q1 2026.